Inhibition of local and systemic inflammatory responses by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS administration in healthy volunteers

12/07/23

Inhibition of local and systemic inflammatory responses by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS administration in healthy volunteers

D.T. de Bruin, M.A.A. Jansen, J. Skillington, L. Tremble, S. Rajbally, N.B. Klarenbeek, M. Moerland...

POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

12/07/23

POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

E. Searle, L.F. Tremble, R. Popat, D.T. de Bruin, M. Moerland, B. Buckley...

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.